---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040628"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:27:58.594898+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tenaya Q2 net loss $33.3M; TN-201 first patient dosing on track for Q3 2023

## Summary
- Cash and investments $151.6M; runway into first half 2025.
- R&D expense $26.5M; G&A expense $8.6M; net loss $0.45/share.
- First patient in MyPeak-1 Phase 1b trial of TN-201 expected in Q3 2023.
- Data from TN-301 Phase 1 trial accepted for HFSA October 2023.
- IND for TN-401 PKP2 gene therapy planned for H2 2023.

## SEC filing metadata
- accession: 0000950170-23-040628
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/0000950170-23-040628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/tnya-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040628
- JSON: https://secwatch.observer/filing/0000950170-23-040628.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040628.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $33.3 million, EPS $0.45 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $33.3 million
  - EPS: $0.45 per share
  - Result: reported results
  source text: Net loss for the quarter ended June 30, 2023, was $33.3 million, or $0.45 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017023040628/0000950170-23-040628-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.